Fig 1.
Study flow diagram.
Table 1.
Baseline characteristics of 159 autoimmune rheumatic disease (ARD) patients and 159 healthy controls.
Table 2.
Frequencies of autoimmune rheumatic diseases (ARD) and current patients’ therapy.
Table 3.
Immunogenicity of fractional-dose yellow fever vaccine (YFV) in autoimmune rheumatic diseases patients and controls.
Fig 2.
Yellow fever vaccine (YFV) viremia after fractional-dose administration (2A and 2B) in ARD patients and healthy controls (HC).
Peak of viremia in seroconverted (SC+) and non-seroconverted (SC-) ARD patients and healthy controls(HC) (2C).
Table 4.
Analysis of factors associated with seroconversion 30 days after fractional-dose yellow fever vaccine (YFV) in ARD patients.
Fig 3.
Longitudinal neutrophils(3A) and lymphocytes(3B) kinetics of ARD patients and healthy controls (HC) after fractional-dose YFV.Values (cell/mm3) represent the mean ± SD of measures for each tiime-point: day 0 or baseline (D0), day 5 (D5), day 10 (D10), and day 30 (D30). The n for ARD patients per day is D0 (n = 159), D5 (n = 148), D10 (n = 147), and D30 (n = 149) and for controls is D0 (n = 159), D5 (n = 158), D10 (n = 156), and D30 (n = 149). *p < 0.05 and ***p < 0.001 compared to day 0 (D0).
Fig 4.
Longitudinal neutrophils(4A) and lymphocytes(4B) kinetics in ARD patients vaccinated for YF, comparing neutropenic vs. non-neutropenic and lymphopenic vs. non-lymphopenic patients. Values (cell/mm3) represent the mean ± SD of measures for each time-point: day 0 or baseline (D0), day 5 (D5), day 10 (D10), and day 30 (D30). *p < 0.05, ** < 0.01 and ***p < 0.001 compared to day 0 (D0).
Table 5.
Local and systemic side effects after YFV in 159 autoimmune rheumatic diseases (ARD) patients and 159 health controls.